Prevalence and Study-Level Predictors of Chronic Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Source: Journal of pain research
Authors: Ryan S D’Souza, Savannah Whitfield, Nasir Hussain, Anuj Bhatia, Dylan W Banks, Jason Parmar, Johana Klasova, Evan Mizerak, Larry J Prokop, Yeng F Her, Publication Date: Wed, 09 Sep 2026 06:00:00 -0400
J Pain Res. 2026 Sep 4;19:643363. doi: 10.2147/JPR.S643363. eCollection 2026.
ABSTRACT
INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating adverse effect of neurotoxic chemotherapy agents. Despite its substantial global burden, the prevalence of chronic CIPN (persisting for ≥3 months after completion of chemotherapy) remains uncertain. We aimed to estimate the global prevalence of chronic CIPN and assess variations based on chemotherapy regimen, cancer type, geographic region, and human development index (HDI).
METHODS: A systematic search of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus was conducted from database inception to May 2025. A random-effects model with Freeman-Tukey transformation was used for meta-analysis. The primary outcome was the global prevalence of chronic CIPN. Subgroup analysis explored prevalence by time since chemotherapy completion, geographic region, chemotherapy regimen, cancer type, and study design.
RESULTS: A total of 197 studies from 36 countries (72,794 patients who received chemotherapy, 26,258 with chronic CIPN) were included. The pooled global prevalence of chronic CIPN was 44.50% (95% CI 40.77-48.25). Subgroup analyses revealed significant variation by geographic region, chemotherapy class, and cancer type. Chronic CIPN prevalence was 54.37% (95% CI 48.24-60.45) at 3-12 months post-chemotherapy, 37.12% (95% CI 30.15-44.26) at 12-24 months post-chemotherapy, and 40.36% (95% CI 34.72-46.08) at ≥24 months post-chemotherapy.
CONCLUSION: Chronic CIPN affects a substantial proportion of cancer survivors, with prevalence influenced by time since completion of chemotherapy, geographic region, chemotherapy type, and cancer type. These findings highlight the need for targeted surveillance, prevention, and management, particularly for high-risk populations.
PMID:42713463 | PMC:PMC13552395 | DOI:10.2147/JPR.S643363
Pubmed ID: pubmed:42713463
Identifiers: pmid:42713463, pmc:PMC13552395, doi:10.2147/JPR.S643363,